Tag: clopidogrel

1. In this randomized controlled trial, medication vouchers were associated with a small increase in patient-reported persistence with P2Y12 inhibitors for patients who had suffered a myocardial infarction (MI). 2. Medication vouchers were not associated with reduced major adverse cardiovascular events (MACE) in these patients. Evidence Rating Level: 1 (Excellent)       Study Rundown:...
1. Use of ticagrelor resulted in similar rates of major bleeding compared to clopidogrel in patients with ST elevation myocardial infarction treated with thrombolysis. Evidence Rating Level: 2 (Good) Study Rundown: Antiplatelet therapy is a major component of management of acute myocardial infarction. Ticagrelor results in greater and more rapid P2Y12...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants The novel oral anticoagulants (NOAC) are an emerging hot topic in medicine given their cost-effectiveness and monitoring preference compared to the traditional vitamin...
Image: PD 1. Prasugrel was more effective than clopidogrel in reducing the incidence of recurrent myocardial infarction in patients presenting with acute coronary syndrome, though there was no difference in mortality between the two groups 2. Patients treated with prasugrel had a significantly higher incidence of fatal major bleeding compared to...
Image: PD 1. The early addition of clopidogrel significantly reduced the incidence of infarct-related arterial re-occlusion within 30 days following myocardial infarction 2. Addition of early clopidogrel improved the outcomes of coronary angiography and decreased the need for early/emergent angiography during the event 3. There were no differences in major or minor...
Classics Series, Landmark Trials in Medicine
1. Treatment with ticagrelor significantly reduces mortality in patients with acute coronary syndrome when compared to clopidogrel. 2. Ticagrelor does not significantly increase the incidence of major bleeding. Original Date of Publication: September 2009 Study Rundown: Clopidogrel is a commonly used medication in the management of acute coronary syndromes (ACS). A previous study...
Image: PD 1. Adding early metoprolol does not further decrease the risk of death post-MI compared to conventional fibrinolytic therapy alone. 2. Use of early metoprolol decreases the risk of reinfarction and ventricular fibrillation, but increases the risk of cardiogenic shock. 3. Adding clopidogrel to aspirin decreases the combined risk of death,...
Classics Series, Landmark Trials in Medicine
1. The addition of clopidogrel significantly reduced the risk of death from cardiovascular causes, nonfatal myocardial infarction, or other ischemic events in patients with ACS without ST elevation. 2. Adding clopidogrel is associated with significantly higher risk of major and minor bleeding, but not life-threatening bleeding. Original Date of Publication: August...